RE: Science Day, 6 May9 Apr 2026 08:53
6103 uses Extecan for its payload, a close relative of deruxtecan. Deruxtecan used in the ADC Enhertu and is highly emetogenic meaning it has a very high risk of causing acute sickness within the first 24 hours after dosing but also up to days later it can be experienced.
Avacta will know if 6103 therefore is being tolerated better than Enhertu. Their is much that can be learned actually early doors and CC seems confident .
People here constantly fretting. Has the half life issue being put to bed now? 🙄